Clinical Trial

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
Protocol Amendment History 32 amendments
This ClinicalTrials.gov record has been amended 32 times since 2024-03-28; most recent amendment 2026-02-24.
Status change: Recruiting → Active, Not Recruiting 2026-02-24
Status change: Not Yet Recruiting → Recruiting 2024-04-30
Trial Details
NCT Number NCT06346067
Lead Sponsor Erasca, Inc.
Conditions Advanced or Metastatic NRAS-mutant Melanoma
Enrollment 78 participants
Start Date 2024-04-29
Primary Completion 2028-04 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-27